Epretide [SS-31, MTP-131, Elamipretide 30mg] – 3 Vials – Corey Pauling

Laboratory: Corey Pauling
Form: Subcutaneous injection
Molecule: Elamipretide (SS-31, MTP-131)
Concentration: 10mg/vial
Volume: 3 vials
Epretide [10mg X 3 vials] contains Elamipretide (SS-31, MTP-131), a mitochondria-targeted tetrapeptide studied for its ability to support mitochondrial function, cellular energy production, ATP metabolism, and oxidative stress management. Its mitochondrial mechanism makes it particularly relevant to research involving endurance, recovery, and physiological stress associated with intensive training.

Description and Effects

EPRETIDE [SS-31, MTP-131, Elamipretide 10mg] contains Elamipretide (SS-31, MTP-131), a mitochondria-targeted tetrapeptide designed to selectively interact with cardiolipin in the inner mitochondrial membrane. By supporting mitochondrial membrane stability and function, Elamipretide has been studied for its potential to improve cellular energy production, support ATP generation, and manage oxidative stress. For athletes and physically active individuals, its primary interest lies in supporting mitochondrial function during periods of intense training and physiological stress.

Product Benefits

• Mitochondrial Support: Supports mitochondrial membrane structure and cellular mitochondrial function.
• Cellular Energy Production: Studied for its potential to support efficient ATP production and cellular energy metabolism.
• Oxidative Stress Management: May help reduce oxidative stress and support cellular protection against reactive oxygen species.
• Recovery and Endurance Support: Its mitochondrial mechanism makes it particularly relevant to research involving physical endurance, recovery, and physiological stress associated with intensive training.

Usage Guidelines

• Reference Protocol: Research-oriented protocols commonly describe 2 to 5mg once daily for lower-dose approaches and 5 to 10mg once daily for higher-dose protocols.
• Frequency: Generally administered once daily by subcutaneous injection.
• Cycle Duration: Research protocols may range from approximately 4 to 8 weeks depending on the intended application.
• Timing: Morning administration is commonly preferred. For protocols focused on training support, administration may be timed approximately 30 to 60 minutes before exercise.
• Administration: Administer subcutaneously according to the selected research protocol.

Precautions and Wellness

• Possible Side Effects: Injection-site reactions, redness, local discomfort, headache, nausea, or fatigue may occur.
• Tolerance: Assess individual tolerance before increasing the dose or extending the duration of use.
• Monitoring: Monitor general tolerance, energy levels, recovery, sleep quality, and any injection-site reactions during use.
• Research Status: Elamipretide remains a research compound, and dosing protocols used in clinical studies vary according to the condition and objective being investigated.
• Storage: Store the lyophilized product according to the manufacturer's instructions. After reconstitution, refrigerate and protect from light.